Microdosing THC for Health & Longevity - Quick Reference Sheet

Microdosing THC for Health & Longevity

Created on 09/29/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Microdosing means small oral amounts of the main intoxicating compound in cannabis, below noticeable intoxication, aimed at health and longevity. Human evidence for a longevity benefit is absent; appeal rests largely on studies in old mice. Better-supported benefits, such as nausea and appetite-loss relief, come from patient groups, mostly at higher doses. Dose-related dizziness, drowsiness, anxiety, and impaired driving are the most consistently documented downsides; microdose risk is unmeasured. (Full Review)

Protocol

Practice range
One-fifth to one-twentieth of a recreational dose
No guideline defines microdosing; dosing guidance starts modestly, increases gradually over up to two weeks, and caps THC near 30 mg daily
Trial-tested regimens
1.5 mg three times daily; 2.5 mg nightly; 7.5 mg once
Dementia (three weeks); sleep apnea; before a laboratory stress task
Time of day
Evening or bedtime is typical
Sleep apnea trial dosed one hour before bed; timing before driving is avoided
Time to effect
Oral onset
0.5–1 hour
Peak effects at 2–4 hours
Sleep apnea severity
Up to 6 weeks
Trial measured changes over up to 6 weeks
Aging-related benefit
Not defined
No timescale is defined for any aging-related benefit in humans

Benefits

Contraindications
  • Pregnancy, attempting conception, or breastfeeding
  • Personal history of psychotic disorder, schizophrenia, or bipolar mania, or a first-degree relative with a psychotic disorder (relative contraindication)
  • Adolescents and adults under 25
  • Cannabis use disorder or other substance use disorder, or a cannabis-use screening score in the hazardous range
  • Ischemic heart disease, arrhythmia, stroke or myocardial infarction within the past 12 months (a conservative cutoff), or symptomatic orthostatic hypotension
  • Seizure disorders or conditions that lower the seizure threshold
  • Recurrent falls (2 or more in 6 months) or frailty
  • Significant liver impairment (Child-Pugh Class B or C)
  • Hypersensitivity to sesame oil or dronabinol when using dronabinol capsules
  • Anyone who must drive or operate machinery within 6 hours of a dose
Key Interactions
  • CYP2C9 and CYP3A4 inhibitors (fluconazole, ketoconazole, ritonavir, grapefruit juice)
  • CYP inducers (rifampin, carbamazepine, St. John's wort)
  • Narrow-therapeutic-index drugs (warfarin, tacrolimus, valproate)
  • Central nervous system depressants (lorazepam, oxycodone, buspirone)
  • Sympathomimetic and cardiac-active drugs (amphetamines, amitriptyline)
  • Blood-pressure-lowering drugs (amlodipine, tamsulosin)
  • Sedating antihistamines and sleep aids, over the counter (diphenhydramine, doxylamine)
  • Decongestants, over the counter (pseudoephedrine, phenylephrine)
  • Sedating supplements (melatonin, valerian, kava)
  • Stimulant supplements (yohimbine, synephrine, high-dose caffeine)
  • Cannabidiol (CBD)
  • Alcohol
  • High-fat meals
  • Other cannabis or hemp products (edibles, delta-8 products)

Risk & Side Effects

  • High: Dizziness, Dry Mouth, and Drowsiness; Anxiety and Negative Mood
  • Medium: Cognitive and Psychomotor Impairment, Including Driving; Psychosis; Cardiovascular Events and Orthostatic Hypotension; Cannabis Use Disorder, Tolerance, and Withdrawal; Fetal and Neonatal Harm in Pregnancy
  • Low: Falls and Impaired Balance in Older Adults; Cannabinoid Hyperemesis-Like Nausea and Vomiting; Seizures and Seizure-Like Activity; Worsening of Depression and Mania
  • Speculative: Male Reproductive Effects; Inaccurate Product Labeling and Unintended Overexposure

Monitoring

Marker Target Why
Resting heart rate 55–70 beats per minute THC can raise heart rate
Blood pressure (seated and standing) Below 120/80 mmHg seated; standing systolic drop under 20 mmHg Detects hypertension and orthostatic hypotension
ALT and AST Each 10–26 U/L THC is cleared by the liver
hs-CRP Below 1.0 mg/L Tracks systemic inflammation, a proposed cannabinoid target
PHQ-9 0–4 Screens depressive symptoms, which THC can worsen
GAD-7 0–4 Screens anxiety, a dose-related THC effect
CUDIT-R Below 8 Screens problematic cannabis use
MoCA 26–30 Baseline cognition for cognitive-aging goals
AHI (only if sleep apnea suspected) Below 5 events per hour Measures breathing pauses, the endpoint in the sleep apnea trial

Cadence: Baseline before starting; 1 week and 4 weeks after starting or changing a dose; then every 3–6 months for heart rate, blood pressure, mood and anxiety scores, and cannabis-use screening; every 6–12 months for liver enzymes, inflammation markers, and cognitive testing

Qualitative Assessment

  • Sleep quality and next-day alertness
  • Mood, anxiety, and stress reactivity
  • Cognitive clarity and memory
  • Dizziness on standing
  • Dose-response diary (timing, dose, effects)